Patient Guide: A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 18 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05544929
Status: 🟢 Enrolling Now
Condition: Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability
Phase: PHASE1

Where You Can Participate

This study is available at 18 locations across the country.

Top locations include:
  • • Boston, Massachusetts
  • • New York, New York
  • • Pittsburgh, Pennsylvania
  • • And 15 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers - Join Clinical Trial NCTNCT05544929

How to Join This Clinical Trial - NCTNCT05544929

Learn how to participate in this PHASE1 trial studying an investigational therapy for Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05544929 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 18 locations. Find a study site near you:

Clinical Research Site

Boston, Massachusetts 02114 - United States

Status: RECRUITING

Clinical Research Site

New York, New York 10015 - United States

Status: RECRUITING

Clinical Research Site

Pittsburgh, Pennsylvania 15232 - United States

Status: RECRUITING

Clinical Research Site

Nashville, Tennessee 37203 - United States

Status: RECRUITING

Clinical Research Site

Toronto, Ontario M5G 2M9 - Canada

Status: RECRUITING

Clinical Research Site

Guangzhou, Guangdong 510080 - China

Status: RECRUITING

Clinical Research Site

Beijing, 100036 - China

Status: RECRUITING

Clinical Research Site

Lyon, 69373 - France

Status: RECRUITING

Clinical Research Site

Dresden, 01307 - Germany

Status: RECRUITING

Clinical Research Site

Essen, 45147 - Germany

Status: RECRUITING

And 8 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Carcinoma, Neoplasms, Melanoma, Carcinoma, Squamous Cell, Nasopharyngeal Carcinoma, Mesothelioma, Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Melanoma, Cutaneous Malignant, Anus Neoplasms, Carcinoma, Renal Cell, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms, Carcinoma, Ovarian Epithelial, Thymoma, Microsatellite Instability:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships